Day One Biopharmaceuticals Inc (DAWN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ...

In This Article:

  • Net Product Revenue: $30.5 million for Q1 2025, driven by OJEMDA.

  • Quarterly Script Growth: 16% increase over the prior quarter.

  • U.S. Revenue Growth: 11% growth in net product revenue quarter-over-quarter.

  • Operating Expenses: $68.9 million, including $12.9 million in noncash stock-based compensation.

  • Cash Balance: $473 million with no debt at the end of Q1 2025.

Release Date: May 06, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

  • OJEMDA achieved significant growth with over 900 quarterly scripts, representing a 16% increase over the previous quarter.

  • Net product revenue for OJEMDA reached $30.5 million in Q1 2025, driven by strong prescriber adoption and high payer approval rates.

  • The FIREFLY-2 confirmatory trial is progressing well, with full enrollment expected in the first half of 2026.

  • Day One Biopharmaceuticals Inc (NASDAQ:DAWN) maintains a strong financial position with a cash balance of $473 million and no debt.

  • The company is actively evaluating business development opportunities to expand its clinical stage portfolio and drive long-term growth.

Negative Points

  • Operating expenses, excluding cost of sales, were high at $68.9 million in Q1 2025, including $12.9 million in noncash stock-based compensation.

  • Seasonality affected Q1 performance, with a slower start in January due to holidays impacting scans and new treatment initiations.

  • Gross to net adjustments were closer to the higher end of the 12% to 15% range, partly due to a price increase and additional co-pay assistance.

  • The market adoption of OJEMDA is gradual, akin to a rare disease launch, due to the infrequency of treatment decisions and longer treatment durations.

  • There is entrenched use of existing therapies, such as chemotherapy and MEK inhibitors, which presents a hurdle to establishing OJEMDA as the second-line standard of care.

Q & A Highlights

Q: What are you seeing in terms of duration of therapy in the marketplace and how do doctors plan to use the drug long-term? A: Lauren Merendino, Chief Commercial Officer, mentioned that while it's early to comment on duration, they continue to see a high percentage of patients remaining on therapy month after month, consistent with the FIREFLY-1 study results.

Q: Can you provide a rough percentage of revenue from new patients versus ongoing patients? A: Jeremy Bender, CEO, stated that the dynamics of new patient starts and patients on treatment are similar to previous discussions, with about 90% on-label and 10% off-label. The focus is on total scripts and revenues as key metrics.